Open Nav

Xyphos Biosciences, Inc.

  • Thorsten Melcher, Xyphos Biosciences, Inc.

Attract investors and strategic collaborators

  • Date:Thursday, October 18
  • Time:10:45 AM - 11:00 AM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Our vision is to provide precision, control, safety and ultimately durable efficacy to CAR-T therapy in cancer. Xyphos is developing treatments for relapsed hematological malignancies and solid tumors using our flexible and controllable CAR-T cell therapy platform called ACCEL™ (Advanced Cellular Control through Engineered Ligands). ACCEL enables precise control of activity and targeting of our universal CAR-T cell, termed convertibleCAR-T™, using any tumor-specific full antibody and can add critical functionality to convertibleCAR-T cells. Building on the success of the pioneer CAR-T therapies, Xyphos is developing best-in-class CAR-T therapy products based on our ACCEL technology which includes our universal convertibleCAR and a family of bispecific, antibody-like adaptor molecules, called MicAbodies™ and MicAdaptors.
  • Company
  • Company HQ City:South San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :XYP-117/217
  • Development Phase of Primary Product:Pre-Clinical
  • Total Amount Raised to Date, In All Rounds:<$10M
Thorsten Melcher
Xyphos Biosciences, Inc.